NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage biopharma company developing oral, non-statin medicines for cardiovascular disease patients, announced its participation in three major investor conferences in June 2025:

1. William Blair Growth Stock Conference (Chicago) - June 3, featuring CEO Michael Davidson presenting a corporate overview at 3:20 PM CT

2. Jefferies Global Healthcare Conference (New York) - June 4, with CFO Ian Somaiya in a fireside chat at 10:30 AM ET

3. Goldman Sachs Healthcare Conference (Miami) - June 9, featuring CEO Michael Davidson and EVP Matthew Phillipe in a fireside chat at 2:40 PM ET

Live webcasts will be available through NewAmsterdam's investor relations website, with archived replays accessible afterward.

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

• William Blair 45^th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 3:20 p.m. CT on Tuesday, June 3.
• Jefferies Global Healthcare Conference 2025 in New York, NY on Wednesday, June 4, 2025. Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 4.
• Goldman Sachs 46^th Annual Healthcare Conference in Miami, FL on Monday, June 9, 2025. Michael Davidson, M.D., Chief Executive Officer, and Matthew Phillipe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:40 p.m. ET on Monday, June 9.
  

Live webcasts of these presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What investor conferences will NewAmsterdam Pharma (NAMS) attend in June 2025?

NewAmsterdam Pharma will attend three conferences: William Blair Growth Stock Conference (June 3), Jefferies Global Healthcare Conference (June 4), and Goldman Sachs Healthcare Conference (June 9).

Who will represent NewAmsterdam Pharma (NAMS) at these investor conferences?

CEO Michael Davidson, CFO Ian Somaiya, and EVP Matthew Phillipe will represent the company at various conferences.

How can investors access NewAmsterdam Pharma's (NAMS) conference presentations?

Live webcasts will be available through NewAmsterdam's investor relations website at ir.newamsterdampharma.com, with archived replays available afterward.

What is NewAmsterdam Pharma's (NAMS) main business focus?

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients with cardiovascular disease and elevated LDL-C cholesterol.